Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306291 · ClinicalTrials.gov registry record · Phase 1
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT02306291: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT02306291 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 91 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02306291, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Mitoxantrone
- DRUG GMI-1271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02306291
The ClinicalTrials.gov registry entry for NCT02306291 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Etoposide is the first listed.
NCT02306291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02306291 about?
NCT02306291 is a clinical study titled "Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML". This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
What is the current status of trial NCT02306291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2015-03. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02306291?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Idarubicin (DRUG), Mitoxantrone (DRUG), GMI-1271 (DRUG).
Who is sponsoring clinical trial NCT02306291?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.